What's in Consorci Sanitari Integral's pipeline?

Consorci Sanitari Integral has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Consorci Sanitari Integral's portfolio?

Top competitors by shared drug class: Shanghai Jiao Tong University School of Medicine.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/consorci-sanitari-integral.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Consorci Sanitari Integral — Portfolio Competitive Intelligence Brief

Consorci Sanitari Integral pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
basal bolus insulin therapy	basal bolus insulin therapy	marketed	Insulin therapy	Insulin receptor	Diabetes

Therapeutic area mix

Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Shanghai Jiao Tong University School of Medicine · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Consorci Sanitari Integral:

Cite this brief

Drug Landscape (2026). Consorci Sanitari Integral — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/consorci-sanitari-integral. Accessed 2026-05-16.